Abivax shares moved higher on Tuesday. The stock rose about 1.8%. The move came after new talk of a possible takeover. Big drug companies are once again being linked to the firm.
A French news outlet claimed AstraZeneca may be lining up an offer. The reported price was €176 per share. That would value Abivax at nearly €13.75 billion. The same outlet had earlier said Eli Lilly was also looking at the company. That earlier figure was close to €15 billion.
Still, investors are not fully buying the story. The stock price is far below levels that would suggest a deal is close. Many traders remember similar rumors from before. Those stories faded quickly. That has made the market more cautious this time.
Abivax’s CEO Marc de Garidel recently addressed the chatter. He brushed it off in an interview with Reuters. He called the takeover talk simple noise. He also pushed back hard on claims involving Eli Lilly. He said there were no talks at all. He added that any such conversation would have been illegal if it had happened.
The French government has also denied past reports. Abivax did the same back in December. Both rejected claims that Eli Lilly had reached out about a possible deal.
For now, the stock is moving on rumors. But clear proof of a takeover is still missing.
